Exploring the Requisites and Design Requirements for Adding ‘Reason for Use’ Information to Prescription Labels by Hussein, Thana
   
i 
Exploring the Requisites 
and Design Requirements 
for Adding ‘Reason for Use’ 












presented to the University of Waterloo 
in fulfillment of the  
thesis requirement for the degree of 
Master of Applied Science 
in 





Waterloo, Ontario, Canada, 2018 
 
© Thana Hussein 2018  




This thesis consists of material all of which I authored or co-authored: see Statement 
of Contributions included in the thesis. This is a true copy of the thesis, including any 
required final revisions, as accepted by my examiners. 
 
I understand that my thesis may be made electronically available to the public  




Individuals with multiple medical conditions and polypharmacy are at higher 
risk of inappropriate prescribing and consequent adverse drug events. Moreover, 
individuals may not adequately understand the therapeutic intention of their 
medications as this information is conveyed to patients inconsistently from their 
healthcare providers. One way to address this problem is to inform the patient of the 
reason for using a prescribed medication. The present research is an initial attempt to 
design a prescription label that incorporates Reason for Use (RFU) by first 
understanding how patients are currently receiving RFU information, their feelings of 
being provided with that information in a future health care system, and secondly, 
exploring their design preferences for this newly designed prescription label. Twenty 
patients (10 female; 10 male) throughout the Kitchener-Waterloo region were 
interviewed using a semi-structured questionnaire and 15 (9 female; 6 male) of these 
individuals participated in a design workshop that aimed to understand where the 
RFU information should be placed on a prescription label, the amount of detail, 
language, and overall layout of the label. Participant responses were analyzed 
thoroughly to discover important and/or frequent themes. Results from the study 
revealed that all 20 patients are in favor of having RFU information shared with their 
pharmacist and overall, would feel more informed if they were provided with RFU 
information from their healthcare providers. Results from the design workshop 
revealed that patients preferred RFU information printed in one to three words (80%) 
with its placement underneath the dosage instructions (33.3%) and/or next to the drug 
name (46.7%) because it felt the most ‘logical’ (73.3%). The participants showed a high 
preference for adding RFU to the prescription label for sake of being better-informed 
and more capable of participating fully in health decisions. Results from this study 
suggest a need for including RFU into the Ontario medication prescribing practices 
and adopting recently released United States Pharmacopeia (USP) patient-centered 
prescription label standards, which also include adding RFU to the labels. 
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Chapter 1 Introduction 
 
The 2006 Institute of Medicine Report, “Preventing Medication Errors,” cited 
inadequate patient comprehension and subsequent inadvertent misuse of 
prescription drugs as a root cause of medication error, meager adherence, and worse 
health outcomes (Institute of Medicine, 2006). Adverse drug events are the cause of 
one in every nine emergency room visits (Zed et al., 2008) and the Canadian health 
care system spends over $2 billion each year on preventable medication-related 
hospitalizations (Hohl et al., 2011). In Canada, 7% of patients, including 30% of older 
adults, take 5 or more medications; a situation commonly referred to as 
polypharmacy (Rotermann, Sanmartin, Hennessy, & Arthur, 2014). Individuals with 
multiple medical conditions and polypharmacy are at higher risk of inappropriate 
prescribing and consequent adverse drug events. With an aging population, the risk 
associated with adverse drug events and preventable health care expenditures will 
only escalate. As the current Ontario health system stands, patients play a major role 
in accurately transferring and communicating medication information; particularly 
those with complex polypharmacy needs must coordinate medications over multiple 
specialists and settings by either providing their own medication lists or bringing in 
their medications when they visit new clinical services. There is a serious potential risk 
to this approach in that patients, particularly in cases of polypharmacy, may not 
understand the therapeutic intention of their medications or they may fail to 
remember the constituent of these discussions. Without a proper understanding of 
the reason a medication is prescribed, healthcare providers are not able to assess if a 
prescription is appropriate or safe. If the patient cannot convey the information to their 
pharmacist or clinician, this jeopardizes the effectiveness of their next health 
treatment or can contribute to medication errors.  
 
When healthcare providers are unable to adequately counsel patients on their 
prescribed medications, or if they forget the constituents of these discussions, 
   
2 
patients may turn to other sources to understand their medications, such as their 
prescription label (PL). Prescription labels are used to communicate key information 
such as medication name, dosage, directions and precautions; they are an immediate 
and important source of medication information to patients, especially when a 
pharmacist, physician or other healthcare professional is not readily available (Law & 
Zargarzadeh, 2010). Labels may supplement or complement healthcare provider 
instructions and medication information leaflets; hence their significance is 
highlighted when either of these two sources of information is not adequate. 
Prescription drug labels, however, are the root cause of a large proportion of 
outpatient medication errors and adverse drug events (Institute of Medicine, 2006). A 
major problem with these labels is that they seldom communicate the reason why 
the drug is being prescribed, also known as Reason for Use (RFU). Prior studies have 
shown that one in eight patients cannot accurately communicate what a medication 
has been prescribed for (Persell et al., 2004); this is almost one in three for older adults 
(Guénette & Moisan, 2011). Most medications have multiple reasons for use which 
have implications for the dose, route, duration, frequency of use, or monitoring.  
 
Since the label typically stays on the medication container throughout the 
entire treatment, the RFU is a useful way of communicating this information to 
patients and helping patients recall the reason they use their medication. Having RFU 
on the prescription label may improve patients’ understanding of their medication use 
and medication-taking behavior, which has the potential to lead to improved safety 
and a reduction in medication errors. The inclusion of RFU would support a better-
informed patient who is more capable of participating fully in health decisions. The 
need for adding RFU has been corroborated in the literature, however, the inclusion 
of such information has yet to be adopted by standardization practices (Institute of 
Medicine, 2006). 
 
The objective of this master’s research was to investigate patients’ 
understanding and feeling towards the inclusion of RFU on medication labels, 
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through semi-structured interviews and exploring the design requirements for an 
improved prescription label, which includes RFU through a design workshop. This is 
the first study to address the design requirements for a prescription label which 
includes RFU, therefore, involving the patients’ views and preferences throughout this 
process is a crucial factor for eliciting a truly patient-centered design. 
 
The following sections of the thesis are briefly introduced below:  
 
Chapter 2 introduces the different design requirements for prescription labels 
which are used to inform the porotype of a newly designed prescription label. 
This chapter also explores how patients are commonly comprehending 
prescription labels, the need for adding RFU on the labels, and the importance 
of involving the stakeholder in such a task. 
 
Chapter 3 discusses how the research methodology used and how the 
investigation was set up and executed.  
 
Chapter 4 presents and discusses the findings from the semi-structured 
interviews with the patient stakeholders. 
 
Chapter 5 presents and discusses the findings from the design workshop with 
the patient stakeholders. 
 
Chapter 6 draws conclusions from the current research project and discusses 
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Chapter 2 Background 
2.1 Introduction 
The purpose of this chapter is to present the current literature of various fields 
of study related to this thesis such as the requirements and the design of prescription 
labels, how patients comprehend labels, and to assess the need for adding RFU onto 
prescription medication labels. Providing consumers with patient-friendly labels that 
include information about indications related to their use has the potential to enhance 
patient safety through the minimization of unanticipated side effects and adverse 
events (Barr et al., 2002). The RFU information, specifically speaking, provides 
pharmacists, patients, and other healthcare professionals with useful information that 
should be considered as a part of supporting the patient’s well-being (Veronin, 2011). 
Standardizing this process is advantageous because medications have multiple 
reasons for use, and the RFU will influence a medication’s route of administration, 
dosing, duration, the frequency of use, and monitoring needs (Wolf, Curtis, et al., 2011). 
The benefits associated with adding RFU to the label allows patients to gain a 
better understanding of why they are being given a medication by their doctors, and 
this enables them to ask questions or refuse the medication if they feel that it is unsafe 
(McNaughton, Huet, & Shakir, 2014). In addition, patients over the age of 65 are more 
likely to have multiple medications for multiple conditions, a condition known as 
‘polypharmacy’. Polypharmacy makes it even more challenging for patients to track 
the purposes of each drug (Burnside et al., 2007). Thus, implementing RFU enables 
patients to collect critical information they need to make decisions about their 
medications by simply looking at the label.  
 
   
5 
2.2 The Design of Prescription Labels 
Currently, in Canada, the Consumers Packaging and Labeling Act is the legislation 
that guides the requirements as to what information needs to be placed on 
pharmaceutical labeling (U.S. Embassies Abroad, 2017). Additionally, Health Canada 
has published guidance documents to aid healthcare professionals on how to comply 
with these governing statutes and regulations (Minister of Health, 2013). At the 
provincial level, the Ontario College of Pharmacists (OCP) provides supplemental 
guidance to pharmacists and pharmacy technicians around labeling and packaging 
prescription drugs (Ontario College of Pharmacists, n.d.). These guidelines are put in 
place to increase the ability of consumers to make informed decisions about their use. 
In particular, the labels must be created in French and English to provide all users 
with an understanding of this information; details about the dealer’s name and 
location of the business, the net quantity of the drug, and the product identity 
declaration must be included.  Similar requirements have been established by the 
Food and Drug Administration (FDA) in the United States (Carpenter, 2014; Institute of 
Medicine, 2006). However, RFU,’ also known as the drug’s indication, is not included. 
Some medication labels in the U.S. may include a note indicating that the patient 
should consult the pharmacist or physician with questions, but this does not ensure 
that the information can be accessed quickly and as-needed. 
Existing recommendations for the optimal design of medication labels are based 
on expertise and sound human-centered design principles (Endestad, Wortinger, 
Madsen, & Hortemo, 2016). When variability is seen between nations, as well as 
deviations from best practices in labeling, there is a need to assess why this is the 
case as well as what could be done to improve the safety of consumers. The United 
States Pharmacopeia (USP) is a standard-setting body that is able to offer information 
about the golden standard of practice in labeling. However, there are about 500 
standard-setting bodies in the United States, contributing to this variability (U.S. 
Pharmacopeia, 2010). Three hundred or so are accredited by the American National 
Standard Institute (ANSI), which is a professional association that watches over all the 
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U.S. standard-setting bodies (ANSI, 2018). At the global level, there is the International 
Standards Organization (ISO) in Geneva, Switzerland (ANSI, 2018; Institute of Medicine, 
2006). A recent meeting held by the Brookings Institution in July 2014 interestingly 
shared findings from multiple independent trials that identified discordance in 
recommendations for a single standard in the format and organization of patient 
medication information (S. C. Bailey, Navaratnam, Black, Russell, & Wolf, 2015). It is 
therefore valuable to assess how medication labels could be designed to better meet 
the needs of patients and to achieve safety as a part of prescribing practices. 
2.2.1 Format, White Space, and Headers 
The literature has revealed that patients prefer that information be organized 
in a schematic, coherent manner (Batchlor & Laouri, 2003; Kalichman, 
Ramachandran, & Catz, 1999; Peterson, Aslani, & Williams, 2003; Rosenthal, Berndt, 
Donohue, Frank, & Epstein, 2002; W. Shrank, Avorn, Rolon, & Shekelle, 2007). The 
logical organization of material on the label is critical; both young and older 
patients tend to prefer information organized schematically, with information 
about the drug, effectiveness, followed by warnings and side effects. Some 
suggestions that patients have offered to researchers pertaining to how these 
labels should be organized have been published in the literature. The most 
commonly, the preferred format for medication labels is the list format as they 
improved patient understanding and recall (Harvard Health, 2007; Hassell, Noyce, 
Rogers, Harris, & Wilkinson, 1998; Melin et al., 2004; W. Shrank et al., 2007; Svarstad, 
Bultman, Mount, & Tabak, 2003). Only one study was found where patients 
preferred the tabular format as shown in Figure 1 (Schwartz, Woloshin, & Welch, 
2009).  
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Figure 1 Example of drug information organized in a tabular format (Minister of Health, 2017) 
 
An additional study that surveyed both older and young adults found that 
patients, particularly the older adults, could more easily read labels that sensibly 
used white space by separating related sections and grouping related material 
together  (Harvard Health, 2007; W. Shrank et al., 2007). Ultimately, this space 
enables the patients to separate concepts and to process the information in a 
manner that is meaningful to them in practice (Sansgiry, Cady, & Sansgiry, 2001; 
Svarstad et al., 2003). For instance, it is essential for patients to be able to locate 
the expiration date on the medication label at all times. When it is expired, it should 
no longer be used, either because the expired formula has the potential to make 
the patient sick, or because the expired medication no longer has the same level 
of effectiveness as it once did, and it is no longer able to produce a treatment 
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effect (Lohiya, 2004). Furthermore, Svarstad et al. (2003) found that patients are 
able to locate information more readily when the different required sections are 
clearly labeled with headers (Hassell et al., 1998; Svarstad et al., 2003; Thomas & 
Corwin, 1998). Overall, when optimizing label format, lists, headers, and white 
space enhance readability, and content should be organized to follow the schema 
that patients use to understand medication information. 
2.2.2 Language 
Although there is no legal specification for wording or directions, the 
complexity of written medication information is problematic since patients 
regularly depend on these materials to figure out how to safely and appropriately 
take prescribed drugs, particularly in the event that physician and pharmacist 
counseling on proper medication use is suboptimal. Therefore, the use of plain or 
lay language on medication labels is highly recommended (S. C. Bailey, Sarkar, 
Chen, Schillinger, & Wolf, 2012; Davis et al., 2009; Dowse & Ehlers, 2001; Gibbs, 
Waters, & George, 1990; M. G. Katz, Kripalani, & Weiss, 2006; Kroner, Kelley, & 
Baranowski, 1994; Mohan et al., 2013; W. H. Shrank et al., 2007; Wolf et al., 2010; 
Wolf, Curtis, et al., 2011; Zargarzadeh & Law, 2011). 
2.2.3 Text Orientation 
The orientation of labeling is important to consider as well. It is important for all 
information to be facing the same direction because this offers the consumer with 
a better understanding of what the information says (Joolaee, Hajibabaee, Peyrovi, 
Haghani, & Bahrani, 2011). It is challenging to physically move the orientation of a 
product to gain an understanding of what the text says, and some will not do this 
and will simply miss information. According to Sanders et al., (1993), the use of 
knowledge about human factors on this subject suggests that it is beneficial to 
have all of the information on the label oriented in the same direction while the 
user is performing the same task (M. S. Sanders & McCormick, 1993). 
   
9 
2.2.4 Contrast/Material 
The literature suggests that the contrast and material may be relevant to 
understanding as well. Haegerstrom-Portnoy et al. (2005) concluded that, “the use 
of high-contrast and nonglossy paper is essential for older adults, considering the 
loss of low-contrast acuity, low-lighting visual acuity and the increased sensitivity 
to glare with age” (Haegerstrom-Portnoy, 2005). 
2.2.5 Use of Images 
Although it is advantageous to consider the needs of patients from a broad 
perspective, people who take medications often have a range of disabilities, and 
some may prevent them from correctly interpreting the labels (Merry & Anderson, 
2011). For instance, it is thought that implementing the use of pictures and symbols 
could be useful for those with vision impairment, and it is also practical to use 
these images as a way to better communicate with those who have difficulty 
reading. Pharmacist guidelines for making medication information accessible for 
patients with vision loss recommend the use of pictures and symbols (American 
Society of Consultant Pharmacists Foundation & American Foundation for the 
Blind, 2018). Results of a recent study ran counter to the hypothesis that older 
adults would find the use of these images more helpful than younger patients 
(Blenkiron, 1996). Instead, young patients reported a greater benefit from the 
combination of images and pictures.  
One potential explanation for the benefits observed by the younger population 
is that symbols used in a mixed format require higher processing demands to 
interpret the information accurately (Burke, 2000; Morrell, Park, & Poon, 1990). 
Additionally, it was thought that young subjects were more proficient at 
integrating the verbal and visual information into a single, consistent storage 
format for later access. Older adults may have also found this more troublesome, 
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potentially on the ground that the distinctive picture- and word-based formats 
competed with one another (Morrell et al., 1990). 
In contrast to the aforementioned studies, Wolf et al. (2010) showed that not all 
pictures are effective at improving patient’s understanding of warning information 
and may not improve the safe administration of medicines (Wolf et al., 2010). 
Ultimately, these findings demonstrate that the addition of a graphic aid to support 
comprehension among the young adults, older adults, or those with limited 
literacy provided no additional benefit and may even impede comprehension 
(Wolf, Davis, et al., 2011). Thus, this specific information should be provided in a 
clearer manner, rather than simply implied on the basis of the additional 
information, such as graphics, placed on the label. As there is currently a 
disagreement in the literature on the use of icons, particularly among older adults, 
to convey medication use (Houts, Doak, Doak, & Loscalzo, 2006; Kutner, 
Greenberg, Jin, & Paulsen, 2006; Morrell & Park, 1993; Daniel G Morrow, Leirer, & 
Andrassy, 1996; Park, Morrell, Frieske, & Kincaid, 1992) there is a need to determine 
how to best resolve these concerns.  
2.2.6 Font 
The preceding sections provided an overview of the considerations that should 
be made when determining whether the medication labels are able to provide the 
necessary information to users in a proper format. A particular concern that arises 
when determining if this is accomplished is whether the font being used for 
labeling is clear and understandable by patients from a variety of age groups and 
demographic backgrounds (Odegard & Gray, 2008).  The font is one of the 
elements that should be considered as a part of this process.  
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2.2.6.1 Font Type 
Shank et al. found that when assessing patients' preferences for three 
font styles for medication labels (Century Schoolbook, Helvetica, and Courier), 
patients preferred Century Schoolbook (Shrank et al., 2007). In this case, each 
letter appeared more distinct, and the participants reported that it was easier 
to read. Additionally, a descriptive survey of 60 older patients presented to 
labels written with five different fonts, the Scriptwriter font was considered the 
most difficult to read (Shrank et al., 2007). Ultimately, this was concluded 
because participants reported that fonts that appeared larger were considered 
easier to read (Shrank et al., 2007). The literature has also revealed that sans-
serif fonts (versus serif fonts) may be more legible by sanctioning improved 
horizontal movement, which is imperative for adults, especially those with low 
vision (Arditi & Cho, 2007; Connolly, 1998). The legibility and recommendation 
of sans-serif fonts is consistent with the results of additional studies (Davis et 
al., 2006; Filik, Purdy, Gale, & Gerrett, 2004; Gerhart et al., 2015; Harvard Health, 
2007; Institute of Medicine, 2006; Latham, Waller, & Schaitel, 2011; Leat, Ahrens, 
Krishnamoorthy, Gold, & Rojas-Fernandez, 2014; Rosenthal et al., 2002; Sansgiry 
et al., 2001; W. Shrank et al., 2007; W. H. Shrank et al., 2010; Smither & Braun, 
1994; Wogalter & Vigilante, 2003). 
2.2.6.2 Font Size 
Medical education guidelines explicitly propose that font size must be 
12-point or larger to optimize the patients’ ability to read health information 
(Doak, Doak, & Root, 1996), but it is worthwhile to consider if it should be even 
larger to better meet the needs of patients with vision problems (Smither & 
Braun, 1994). In an experiment conducted with 19 young and 20 older patients, 
patients of all ages preferred labels written in a larger font and reported that 
14-point font was easier to read than 12 point, which was easier for them to read 
compared to the 9-point. This survey also found that patients read labels with 
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a larger font more quickly and precisely than labels with smaller font (Shrank 
et al., 2007).  By and large, discoveries in the literature suggest that larger text 
dimension is ideal (Harvard Health, 2007; Institute of Medicine, 2006; Kalichman 
et al., 1999; Latham et al., 2011; Law & Zargarzadeh, 2010; Leat et al., 2014; 
Rosenthal et al., 2002; Sansgiry et al., 2001; W. Shrank et al., 2007; W. H. Shrank 
et al., 2009, 2010; Wogalter & Vigilante, 2003; Wolf et al., 2007; Zargarzadeh & 
Law, 2011). 
2.2.6.3 Tall Man Lettering and Capitalization 
An additional font suggestion that has been made in the literature is 
regarding the use of tall man lettering. Tall man lettering is the practice of 
writing part of a drug's name in upper case letters to highlight its primary 
dissimilarities and to help distinguish sound-alike, look-alike drugs from one 
another in order to avoid medication errors (Grissinger, 2012). For example, 
"prednisone" and "prednisolone" in tall man lettering would be "predniSONE" 
and "predniSOLONE", respectively. A 2004 study demonstrated that when 
patients are presented with 'tall man" letters, they are half as likely to 
incorrectly identify the information, (Filik et al., 2004), suggesting that 
capitalizing sections of potentially confusing drug names improves 
identification and readability.  The Institute for Safe Medication Practices (ISMP), 
FDA, and other safety-conscious organizations such as the National 
Association of Boards of Pharmacy (NABP) have recommended the use of tall 
man letters as one means of reducing confusion between similar drug names 
(Institute for Safe Medication Practices, 2002, 2003; National Association of 
Boards of Pharmacy, 2008; U.S. Food and Drug Administration, 2009). 
One other study found that the use of capital letters may result in 
speedier reading when comparing equivalent size in point print in sentence 
case for both people with and without visual impairment (Arditi & Cho, 2007). 
However, this same study also stated that capital letters may reduce the clarity 
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of the label. The general guidelines from professional organizations also 
recommend conflicting results (Canadian National Institute for the Blind, n.d.; 
Royal National Institute for Blind People, 2014; U.S. Pharmacopeia, 2012), 
therefore, the optimal use of sentence case versus capital is still not confirmed 
(Leat et al., 2014). 
2.2.6.4 Legibility 
Furthermore, the legibility of information is a clear concern (Leat et al., 
2014). In spite of the fact that there are rules for general print intelligibility from 
nongovernmental associations and particularly for medication labels from 
some pharmaceutical and health organizations, they may not be applied 
consistently to medication labels (Leat et al., 2014; Punsongserm, Sunaga, & 
Ihara, 2017). In some instances, guidelines are considered suggestions rather 
than required practices, which contributes to this challenge. For instance, in 
Ontario, there are no legal prerequisites regarding the legibility of print, 
although the content of what must be included on the label is specified 
(Service Ontario, 1990). This means that different pharmacies are able to follow 
different labeling standards, and this has the potential to contribute to 
confusion among patients. Research has demonstrated that many of the 
current labels use sans-serif fonts, nonglossy paper, and a high contrast (Leat 
et al., 2014), however, the points discussed in the following sections are highly 
variable from pharmacy to pharmacy. Generally, the literature agrees upon the 
importance of increasing legibility of the fonts to support the reading abilities 
of patients who have visual impairment (Arditi & Cho, 2007; Connolly, 1998; 
Latham et al., 2011; Leat et al., 2014; Lohiya, 2004; Punsongserm et al., 2017; W. 
Shrank et al., 2007; Smither & Braun, 1994; Wogalter & Vigilante, 2003). 
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2.2.7 Emphasis 
Label items that are most emphasized are those that enrich the practice of 
the pharmacist, and not the items that patients need to safely and appropriately 
administer medication (Shrank et al., 2010). Shrank et al. inspected the variability in 
label content and format when identical prescribed medications were dispensed 
at 85 different pharmacies. The study found that the current labeling system 
highlighted material important to the provider (e.g., pharmacy logo and 
prescription number rather than information that supports understanding and 
proper use of the medication (W. Shrank et al., 2007). The inclusion of such 
distracting material may be exceptionally problematic for patients with limited 
literacy, who face greater reading difficulty in less familiar and technical contexts  
(Doak et al., 1996). Ultimately, different providers place different levels of emphasis 
on the information related to medication use, so these challenges can vary. 
2.2.7.1 Bolding 
In the study conducted by Leat et al. (2014), “bolding was used in 95.6% 
of the labels, but was not used to strictly emphasize the patient- critical 
information, as recommendations would suggest. All of the labels that used 
bolding had at least one of the patient-critical components bolded; however, 
none of the labels bolded only the patient-critical information” (Leat et al., 2014). 
It is reasonable to use the bolding technique in order to help patients 
understand what information is absolutely essential, such as safety information. 
However, it is necessary for this to be consistent because if the information is 
bolded using different patterns at different pharmacies, then it will be 
challenging for patients to gain a true understanding of how to use this 
information to take their medications properly. As a result, it might be 
advantageous to limit the use of bolding and highlighting, because any 
information placed on the label is important to the patient. 
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2.2.7.2 Italics and Underlining 
Just as bolding is not highly recommended by professionals in the 
literature, italics and underlining are not either (American Society of Consultant 
Pharmacists Foundation & American Foundation for the Blind, 2018; Canadian 
National Institute for the Blind, n.d.; I. R. Katz et al., 1998; Royal National Institute 
for Blind People, 2014). Although these are alternative methods for 
emphasizing information, it is apparent that emphasizing any information could 
detract the reader from additional information that may not be emphasized 
using these methods (Wallace, Keenum, & DeVoe, 2010). As such, the use of 
italics and/or underlining does not fall into the suggestions for labeling by 
common guidelines in North America (Leat et al., 2014). A summary of the 
generally agreed upon guidelines for designing prescription labels can be 
found in Table 1. 






Maximize white space 
Logical Organization 
Language Plain/lay language 
Text orientation Horizontal 
Alignment Left justification 
Paper material Nonglossy 
Contrast High 
Font type Sans-serif 
Font size Minimum 12 or 14 points 
Font color Black 




   
16 
2.3 Comprehending Prescription Labels 
Given that the health information label is an important component of health 
care practice, it is important to ensure that the information could be used by 
patients. Several studies determined that patients most often had questions about 
adverse effects, indication, and dosing frequency (B. J. Bailey et al., 1997; Lyons, 
Rumore, & Merola, n.d.; Morris, Tabak, & Gondek, 1997; Shrank et al., 2007; Sleath, 
Roter, Chewning, & Svarstad, 1999) which demonstrates that even though the 
information is consistently found on the medication label (excluding indication), 
patients don’t understand it or know where to find it (Lyons et al., 1996).  
Some patients believe that comprehending a prescription label is  a simple 
task, as a result, they may not allow adequate time to process and understand the 
information (Wolf et al., 2007); it is also important to consider the perspective of 
the patients that may experience extreme difficulty in doing so. Related to this 
concern, Morrell et al. (1990) determined that older adults, a population that is 
more likely to be taking multiple medications, are at an increased risk for safety 
concerns related to pharmaceutical use because they do not necessarily take the 
amount of time that is needed for them to fully understand the labels (Morrell et 
al., 1990). By thinking from the perspective of the patients rather than the 
healthcare professionals who write and fill these prescriptions, it is possible to 
better meet the needs of the patients. This lack of comprehension is more 
common than healthcare professionals may expect (Rapp & Samuel, 2002; Rapp 
& Van Den Broek, 2005; Van Den Broek & Kremer, 2000). 
The particular features that should be considered as a part of the 
comprehension process include the cognitive skills of the patients, especially 
those of older age as aging reduces information processing capacity. 
Furthermore, there may be physical constraints that block the person from being 
able to read the label, such as the lighting in the room. It is important for labels to 
be designed in a manner that allows the information on them to be accessible by 
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patients in a range of situations. Formatting and organizational issues should also 
be considered.  
An additional concern is that there is some confusion about dosage 
information. Some healthcare providers use abbreviations for this purpose, but the 
average person doesn’t understand what these mean (Wolf et al., 2010). Thus, all 
abbreviations should be written out, rather than using the medical abbreviations 
used to prescribe them. It is important for patients to comprehend the need for 
them to review these labels when they are being given new drugs or being 
presented with changes to their existing medications. This will help them avoid 
errors that could cause harm to their health. 
An interesting issue that is related to the topic of labeling relates to not only 
the presence of this information, but how it might be interpreted by the patient 
(Wolf et al., 2010). Failure may occur if instructions are not explicit, or if purpose is 
not evident, such as providing an indication for use on the bottle label itself (i.e. 
‘‘take for diabetes’’); including such information is not part of routine practice for 
either physicians (to add to the prescription send to the pharmacist) or pharmacists 
(to include on the dispensed container label). Even when an indication is included, 
it still is not explicit enough. In particular, something that says it should be taken 
for diabetes does not provide the user with an understanding of what the 
medication is explicitly treating. One may assume that it is an insulin treatment and 
it is meant to treat diabetes itself, or it may be an antibiotic that was prescribed to 
help resolve an infection related to diabetic ulcers. By providing patients with at 
least a simple understanding of the mechanism of action in addition to this 
information, it is possible to increase the safety of use.  
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2.4 Improving Prescription Labels 
To transition to the practice of providing clear and detailed labels on 
medications, it is necessary for professionals to recognize that there is a gap 
between what the field could accomplish and the problems that are inherent in 
the present labeling processes. Although the literature has shown that patients 
heavily refer to their prescription label for key information and that a piece of 
information that they would like to see on the label is RFU (American Pharmacists 
Association, 2017; Basara & Juergens, 1994; Burnside et al., 2007; Cardarelli et al., 
2011; Institute of Medicine, 2006; Law & Zargarzadeh, 2010; Luscombe, Jinks, & 
Duncan, 1992; Mohan et al., 2013; Rosenthal et al., 2002; Sakharkar, Zargarzadeh, & 
Law, 2014; Schiff, Seoane-Vazquez, & Wright, 2016; W. H. Shrank et al., 2010; U.S. 
Pharmacopeia, 2010; Zargarzadeh & Law, 2011). In recognition of this, the United 
States Pharmacopoeia (USP) published, in November 2010, a  General Chapter on 
prescription container labeling, stating the label should include a “purpose for use” 
based on patient preference (U.S. Pharmacopeia, 2010), however, there is no study 
conducted on the design of implementing such. When patients are asked whether 
they want to better understand the use of a medication or the information on a 
label, most patients report that they do, Thus, it is important to consider how 
specifically to change labels to offer a consistent and clear way to provide patients 
with more information about their medications.  
 
2.5 Implementing Reason for Use on Prescription Labels 
To understand the impact of placing reasons for use on prescription labels in a 
clear manner, it is first necessary to define the extent to which patients require 
these labels to gain an understanding of essential information from these bottles. 
It is still possible for patients to access information about RFU, but one of the most 
common ways that they accomplish this is by asking it of their physicians (Yi et al., 
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2015). Given that physicians have a limited amount of time to accomplish this, 
these individuals may not be getting the information that they need to take their 
medications safely.  
To characterize this problem, research was conducted to determine the length 
of time physicians spend communicating with their patients about their 
prescription drug use. It was determined that these sessions lasted approximately 
four minutes long. In addition, half of the patients tend to not ask questions about 
drug use, but of those who do, it was determined that their questions primarily 
pertained to information already present on the label. However, 80% of patients 
had questions about use, demonstrating that this information represents the 
greatest source of missing information for patients (Chovil & Altekruse, 1986). 
While patients ideally should receive information about their medications from 
physicians and pharmacists, there is considerable evidence that physicians and 
pharmacists frequently miss opportunities to adequately counsel patients on 
newly prescribed medicines (Law & Zargarzadeh, 2010; Makoul, Arntson, & 
Schofield, 1995; Metlay et al., 2005; Morris et al., 1997; Scherwitz, Hennrikus, Yusim, 
Lester, & Vallbona, 1985; W. Shrank et al., 2007; Sleath et al., 1999; Stevenson, Cox, 
Britten, & Dundar, 2004; Tarn et al., 2006).  
Conversations with the patient are helpful because they promote clarification 
of their understanding in a manner that contributes to better outcomes. Although 
physicians, pharmacists, and other healthcare providers may have limited time to 
spend with individual patients in many cases, it is reasonable for them to provide 
patients with handouts with additional information. However, these documents are 
helpful only when they are able to provide information that is easily 
understandable by the patient. Some of these documents use medical 
terminology which consists of Latin derivatives and additional words that are not 
spoken in the vernacular (Mitrovic, 2014) meaning they are fairly challenging to 
comprehend for the average patient (Bernardini, Ambrogi, Perioli, Tiralti, & 
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Fardella, 2000; Buck, 1998; Dickinson, Raynor, & Duman, 2001; Estrada, Hryniewicz, 
Higgs, Collins, & Byrd, 2000; Gustafsson, Kalvemark, Nilsson, & Nilsson, 2005). 
When patients cannot access RFU information from healthcare professionals, 
they may attempt to do so in an informal manner. For example, the Food and Drug 
Administration (FDA) website or the American Association of Retired Persons 
(AARP) Guide to Pills serve as excellent resources for patients who may have 
additional questions to make them feel confident about their pharmaceutical use. 
However, some individuals may not able to access these resources based on their 
technological capabilities, and some may have difficulty understanding the 
information available on the website (Ayantunde, Welch, & Parsons, 2007). 
Therefore, the container label plays an important role in the appropriate 
administration of prescription medication (Shrank et al., 2007). Unlike the 
supplemental leaflets, which patients can easily discard or ignore (Institute of 
Medicine, 2006), the container label usually remains with the medication during 
the course of therapy. They often serve as the only or “last line” source of 
medication information (Wolf et al., 2007) and, undoubtedly, play an vital role in 
increasing patients’ understanding of their medication (Hong, Liu, Tak, & Vaidya, 
2013; Mohan et al., 2013; Shiyanbola, Smith, Mansukhani, & Huang, 2016; 
Zargarzadeh & Law, 2011). This demonstrates that the labels serve as a source of 
important information in many cases, and this information may prompt the patient 
to do additional research of their own when they are not certain about the RFU. 
Thus, it is apparent that healthcare professionals, as well as federal agencies, 
may not be fully considering the needs of the patient when considering what 
requirements should be in place for medication labeling (Wolf, Curtis, et al., 2011). 
When considering the specific needs of patients, it is worthwhile to consider that 
aging has a negative impact on memory, and older patients are not always going 
to be able to recall the RFU information from a visit with a physician (Gustafsson 
et al., 2005). It is important for healthcare professionals and those responsible for 
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labeling to understand that patients need a reminder of use in order to ensure that 
they are compliant with instructions. Helping patients understand what 
medications they are on and why can increase outcomes in this manner.  
 
2.6 Involving the Stakeholders 
 
The stakeholders involved in this issue includes the physicians and prescribers, 
non-prescribing healthcare professionals, patients, governments, and 
pharmacists. Opinions from healthcare professionals and patients may lead to 
improved labels by providing their understanding of medication information 
(American Pharmacists Association, 2017; Andre & Wickens, 1995; S. C. Bailey et al., 
2015, 2012; Davis et al., 2006; Gerhart et al., 2015; Hong et al., 2013; Leat et al., 2014; 
Mohan et al., 2013; Shiyanbola, Smith, Huang, & Mansukhani, 2017; Wolf, Curtis, et 
al., 2011; Zargarzadeh & Law, 2011). Physicians and prescribers have found that 
increasing the detail and accuracy of medical labeling for products that they are 
responsible for administering helps reduce medication errors (Bauer & Guerlain, 
2011). Since physicians benefit from increased accessibility to RFU information, it 
is intuitive that patients would benefit from this change as well. Nurses and other 
healthcare professionals are typically responsible for providing patients with 
information about their medications and instructions for use during discharge, and 
this effort is more likely to be effective if patients are reminded of this information 
when they are accessing their medications (Bekker, van den Bemt, Egberts, Bouvy, 
& Gardarsdottir, 2018). 
 
Patients are impacted because it is expected that they will be able to 
experience an improved quality of care through reduced errors and increased 
safety (Bauer & Guerlain, 2011). The government also plays a key role in the 
regulation of prescription medications through the Food and Drug Administration 
(Stafford, 2008). A decision that all prescription medications must contain the RFU 
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would, therefore, occur at this level and have the potential to impact the other 
stakeholders. Finally, pharmacists and pharmacy employees play a key role 
because they would be responsible for transferring the information that the 
prescriber gave them about RFU onto the prescription label, and they must do so 
accurately and in a manner that helps the patient notice this information (W. H. 
Shrank et al., 2009). It is expected that including the RFU on the labels will reduce 
medical costs for patients, as well as limit readmissions in a manner that allows 
healthcare professionals to respond to fewer cases related to accidents (Bauer & 
Guerlain, 2011). The pharmacies may incur small costs associated with this change, 
but it will allow for a better long-term benefit (W. H. Shrank et al., 2009). Thus, the 
federal regulators such as Health Canada and the U.S. FDA may need to become 
involved to mandate this change, since there is little incentive for pharmacies to 




Overall, the literature has revealed that there should be a place for the RFU on 
the labels of all medications and that it is necessary to do so in a manner that is 
understandable for all patients. It is necessary for Health Canada, the FDA, and 
other regulatory agencies to collaborate and identify the best methods to ensure 
clear communication of the medication name, dose, use, and safety information, 
in addition to other features to patients. Furthermore, given that people who use 
medication are more likely to have impairments than those who don’t, it is 
essential to consider the difficulty that patients with age- and disease-related 
disabilities may have in terms of their abilities to access the information on a label. 
Having the information available in a large font with the use of simple vocabulary 
will promote this purpose. While there is a growth in the popularity of accessing 
online information to learn more about the function of a drug as well as additional 
information, this data is not always presented in a way that the average user could 
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understand. When this information is not placed adequately on the prescription 
label, patients may be missing this information, leading to noncompliance. It is 
therefore essential to put forth efforts to address these issues to promote better 
patient safety and outcomes. 
Ultimately, by defining the specific changes that should be made by evaluating 
an improvement in patient understanding based on the labeling practices applied, 
it will be possible to confer a significant increase in practice quality that could lead 
to improved health for all patients. Treatment compliance is necessary to see 
these improved outcomes, and the understanding and accessibility of information 
on the basis of how it is labeled for consumers have the potential to cause a drastic 
positive change. While a barrier to implementation may be the cost of the research 
process needed to accomplish this at the policy level, it is possible to use 
recommendations from the literature as well as information from consumers to 
gain a better understanding of how these needs could be addressed by 
professionals in practice.  
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Chapter 3 Method  
 
To be able to design a patient-centered medication label which includes RFU, 
it is imperative to involve the principal stakeholders, which are the patients. Co-design 
is a user-centered design approach which involves stakeholders (businesses or 
customers) working together in the design development process to collectively 
develop new solutions (E. B.-N. Sanders & Stappers, 2008). Recent research suggests 
that designers working within a co-design environment create more innovative 
concepts and ideas than they do when creating ideas on their own (Mitchell, Ross, 
May, Sims, & Parker, 2016; Trischler, Pervan, Kelly, & Scott, 2018). 
 
The co-design approach used for this project reconciles the user’s tacit 
knowledge and preferences in hopes to build an improved, patient-friendly 
medication label. This design approach is customarily an iterative method which 
judiciously assesses the impacts of these incremental design changes. The process 
of such, involves the following: 1) an initial exploration of work where designers and 
users familiarize themselves with one another, 2) a discovery process in which the 
designer and users employ various techniques to understand the problem, and 3) a 
prototype stage in which the designers and users iteratively shape artifacts to solve 
the aforementioned problem (Spinuzzi, 2005). The co-design process used for this 
research study will solely focus on a discovery stage through a semi-structured 
interview and a prototyping stage through a design workshop. 
 
 
3.1 The Participants 
 
Between March 2018 and July 2018, two researchers (including the author of this 
thesis and one other research student) recruited a convenience sample of twenty 
individuals (10 females; 10 males) throughout the Kitchener-Waterloo region in 
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Ontario, Canada. Participants were recruited through emails, posters, and through the 
Waterloo Research in Aging Participants Pool (WRAP). The age of the participants 






18 of the 20 interviews and design workshops took place in an empty room located 
in EC4 at the University of Waterloo; the remaining two sessions were conducted at 
the participants’ preferred location in the Kitchener/Waterloo region. Each of these 
locations was chosen for the sake of maximizing privacy and minimizing distractions. 
An audio recorder was used through the entire session. During the design workshop 
phase, participants were provided with sharpies, markers, scissors, tape, glue, a blank, 
prescription label template and a prescription label prototype which was created 
following the guidance obtained from the literature (see Appendix G), and cut-outs of 
common prescription label elements (see Appendix H). Once all the interviews and 
workshops were completed, the audio recordings were uploaded to a password-
protected file and deleted from the audio recording device; pictures of the design 
creations were taken and uploaded to a secure online location and the physical 





Each session began with providing the participants with a copy of the information 
and consent form (see Appendix D and E) and offering them an opportunity to ask any 
questions or express any concerns. After obtaining consent, the researchers indicated 
to the participant that the audio recorder would be turned on, signifying that the 
session would officially commence. The duration of the sessions ranged from as short 
as 10 minutes to as long as 68 minutes.  
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3.3.1 Discovery through Semi-Structured Interview 
 
All 20 participants took part in the semi-structured interviews. Individual 
interviews were conducted with each participant and two researchers 
(including the author of this thesis). Interview questions were formed and 
validated by the author of this thesis and research experts at the University of 
Waterloo’s School of Pharmacy and Systems Design Engineering Department. 
The questions were divided into three sections (see Appendix G). The first 
section focused solely on the participant’s demographics and medication 
history. If the participant had a medication list and was comfortable with sharing 
this information with the research team, the researchers took a picture with all 
identifying information removed. The next phase of questions was regarding 
how patients interact with the current health care system, with a keen 
emphasis on RFU. The last phase of the interview portion focused on a future 
health care system that would, hypothetically, include the RFU. All questions 
were designed to be open-ended to provide the participants with more 
autonomy to share their experiences, desires, and concerns. Throughout each 
phase of the interview, when appropriate, the researchers would ask probing 
questions to clarify about specific details, and/or to elicit deeper discussions. 
 
3.3.2 Prototyping through a Design Workshop 
 
A modification for this study, which requested for the inclusion of a 
design workshop (see Appendix I), subsequent to the semi-structured 
interview, was solicited and approved on May 11th, 2018. Of the 20 participants, 
15 also took part in this design workshop. The workshop phase of the study 
focused primarily on prescription labels which included adding the RFU and 
rearranging the label to better cater to patient needs and preferences. The 
workshop and interview questions were formed by the author of this thesis and 
validated by research experts at the University of Waterloo’s School of 
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Pharmacy and Systems Design Engineering Department. Workshop tasks 
specifically aimed to explore the following: the language, amount of detail, 
location, the presentation of the reason for use information, and the overall 
layout preference of prescription labels. Participants were encouraged to talk 
aloud during the workshop to assist the researchers in understanding their 
design-decision making processes. After the design portion, a semi-structured 
interview was carried out in regards to adding RFU onto prescription labels.  
 
Lastly, participants were given the opportunity to express their final 
thoughts, comments, and/or concerns or return back to a discussion which 
they felt they had more to say about. At the completion of the sessions, the 
participants were thanked, provided with a feedback form (see Appendix J), 
and provided with a $25 honorarium. 
 
 
3.4 Data Analysis 
 
Since this work is highly qualitative in nature, an analysis framework (Braun & 
Clarke, 2006) was applied to discover important, frequently mentioned responses. 
The analysis strategy conducted by the author of this thesis included: 1) carefully 
listening to and recording verbatim participant responses, 2) categorization of major 
problems/responses, and 3) recording the frequency of problems/responses for 
each question. By using this analysis framework to distill data, the researcher 
determined broad patterns that allowed for the transmission of more granular 
research and descriptive, statistical analysis (percentage, mean). That being said, the 
frequency of participants responses was statistically analyzed to understand the how 
patients currently interact with the system and the bearings of adding RFU into the 
health care system (Chapter 4). Design outputs from the workshop were analyzed and 
compiled into a single pictorial; frequency of participants responses was statistically 
analyzed to understand the design and associations of adding RFU onto prescription 
labels (Chapter 5). 
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Chapter 4 Discovery Findings from Semi-
Structured Interviews 
 
In the following chapter, a detailed analysis of this qualitative research study is 
presented which sets out to understand the background behind RFU, supporting the 
primary research question of how to add RFU onto prescription labels. The purpose 
of this study is to understand how RFU information can be included in Ontario’s health 
care system to enhance patient understandings of their medication and to improve 





4.1.1 Description of the patient stakeholder sample 
 
A total of 20 participants took part in the semi-structured interview. Half 
of the participants were female and half were male; the mean age of the 
participants was 59 years. As seen in Table 2, 10% of the were currently taking 
one or two prescribed medications, 35% were currently taking three or four 
prescribed medications; 30% were currently taking five or six prescribed 
medications; 20% were currently taking seven or more prescribed 
medications. Participants were currently taking an average of 4.65 prescription 
medications. Fourteen (70%) participants provided a list of their prescribed 
medications. Patients were further tested on their understanding of their own 
medications by going through each one independently and stating the RFU; of 
those taking one or more prescribed medications, seventeen (86.7%) assuredly 
stated the RFU for their medications  
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Table 2 Stakeholder demographics (n=20) from semi-structured interviews 
 
 Frequency (%) 
Age (in years)  
21-30 3 (15%) 
31-40 3 (15%) 
41-50 2 (10%) 
51-60 0 (0%) 
61-70 3 (15%) 
71-80 4 (20%) 
81+ 5 (25%) 
Mean 59 years 
Gender  
Male 10 (50%) 
Female 10 (50%) 
Number of current prescribed 
medications 
 
0 1 (5%) 
1 1 (5%) 
2 1 (5%) 
3 5 (25%) 
4 2 (10%) 
5 3 (15%) 
6 3 (15%) 
7+ 4 (20%) 
Mean 4.65 
Keeps a list of medications  
No 6 (30%) 
Yes 14 (70%) 
Assuredly states RFU of their 
medications (n=19) 
 
No 2 (10) 
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4.1.2 Current Ontario Health Care System 
 
The majority of participants (N=16, (80%)) stated that they usually receive 
RFU information from the prescribing physician; eight (40%) stated that they 
receive this information from the pharmacist; seven (35%) shared that they 
retrieve this information from supplemental materials given from the 
healthcare providers or online. Upon receiving this information, 85% of the 
participants stated they store this information in their memory and 25% shared 
they keep a medication list handy, or store this information in a file at home. As 
shown in Table 3, participants recalled that RFU information was shared with 
them in the past by physicians (80%) and/or the pharmacist (60%); but three 
(15%) participants disclosed that they did not recall this information being 
shared with them. The participating patients recalled that the RFU information 
was openly communicated by the physician (75%) or pharmacist (50%) when it 
was a newly prescribed medication. Seven (35%) stakeholders only recalled 
receiving this information from healthcare providers upon asking. Six (30%) 
stakeholders recalled receiving RFU information freely from a healthcare 
provider while 12 (60) expressed that they had to ‘sometime’ or ‘always’ ask for 
this information. The majority (85%) of the participants recalled receiving this 
information in laymen terms and could not recall a time that the information 
was not clear or useful (75%). Sixteen (80%) of the stakeholders could recall a 
time that learning about RFU was helpful for them and 15 (75%) could not recall 
a time when they did not know the reason for using a medication. The majority 
(80%) of the participants shared RFU information with their family and/or 
partner. On average, the stakeholders rated the importance of knowing RFU as 
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Table 3 How stakeholders interact with the current Ontario health care system 
 
 
Question Frequency (%) 
Responses to interview questions  
How do you currently find out what 
your medications are for? 
 
From physician 16 (80) 
From pharmacist 8 (40) 
Supplemental material (from     
healthcare provider) 
2 (10) 
Online 5 (25) 
Where do you place this information?  
Memory 17 (85) 
File at home 4 (20) 
Medication List 1 (5) 
In the past, has the reason for use 
information been shared with you? If 
yes, by who? 
 
Never shared 3 (15) 
Yes, by the physician 16 (80) 
Yes, by the pharmacist 12 (60) 
When did they share it?  
Physician, new med 15 (75) 
Pharmacist, new med 10 (50) 
Pharmacist, refill 1 (5) 
Pharmacist, annual review 3 (15) 
Upon asking 7 (35) 
Did you have to ask to find out or was 
this information provided freely? 
 
No 6 (30) 
Sometimes 9 (45) 
Always 3 (15) 
‘I do not ask’ 2 (10) 
Type of language used to explain RFU   
Lay Language 17 (85) 
Medical Language 5 (25) 
Was there a time that the reason for 
using a medication a professional 
provided was not clear or useful? 
 
No 15 (75) 
Yes 5 (25 
Can you recall a time that learning the 
reason for using a medication was 
particularly helpful for you? 
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No 4 (20) 
Yes/always 16 (80) 
Can you recall a time when you did 
not know the reason for a medication?  
 
No 15 (75) 
Yes 5 (5) 
Who else is aware of the reasons you 
are taking your medications? 
 
Family/Partner 16 (80) 
Friends/Coworkers 3 (15) 
Nobody 1 (5) 
On a scale of 1 to 5, with 5 being “very 
important,” how important is it for you 






4.1.3 Adding RFU into the Ontario Health Care System 
 
All of the stakeholders felt positive about the sharing of RFU information 
by a pharmacist. Sixteen (80%) preferred getting this information on a printed 
medication list; thirteen (65%) stated they would like to have access to their 
medical record online through a website and/or an app; seven (35%) would 
appreciate having the RFU information on their prescription label. Having 
access to their RFU information would make all stakeholder feel more 
informed; eleven (55%) felt like having access to this information would help 
them weigh their medication options or affect the adherence to the drug 
regimen. Fourteen (70%) would like other medical staff (beyond their physician 
and pharmacist) and emergency personnel to have access to their RFU 
information; eleven (55%) would like their family and/or partner and five (25%) 
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Table 4 Stakeholder's views on a future health care system which includes RFU 
 
 
Question Frequency (%) 
Responses to interview questions  
How would you feel if the reason for 
use was shared with your pharmacist 
on every prescription, including 
refills? 
 
Negative o (0) 
Positive 20 (100) 
How should the reason for use 
information be presented to you? 
 
On printed medication List 16 (80) 
On pharmacy receipt 0 (0) 
On an online medical record 13 (65) 
Through email 1 (5) 
Mentions prescription label 7 (35) 
How would the reason for use 
information affect your ability to make 
decisions about your medications? 
 
‘Be more informed’ 20 (100) 
Weigh options 5 (25) 
Adherence 6 (30) 
Who else should have access to your 
RFU information? 
 
Medical staff (outside of the primary  
physician or pharmacist) 
7 (35) 
Emergency personnel 7 (35) 
Caregivers 5 (25) 






 In this qualitative study, patients discussed how they interact with the current 
Ontario health care system and their views on a future system that would include 
RFU. Given the growing challenges of polypharmacy and the increasing older adult 
population, patients need to be key members of the decision-making team. Shared 
decision-making refers to a form of health care decision-making where the patient 
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and the practitioner make a choice together that is informed by both the available 
evidence and the patient’s values and preferences (Charles, Gafni, & Whelan, 1999; 
Towle & Godolphin, 1999). It can be as complex as choosing a new treatment or as 
simple as adjusting the time of day of a medication. a crucial step in recommending 
the right treatments to patients is for healthcare providers take the time to identify the 
patient preferences and values (Mulley, Trimble, & Elwyn, 2012). Although the 
research from the literature has shown that physicians and pharmacists do not 
adequately assist their patients due to time constraints, the majority of participants 
stated that they receive RFU information from their physician, or receive this 
information from the pharmacist upon pick up. What’s unique about these 
occurrences, however, is that the healthcare professionals are only providing this 
information when a medication is newly prescribed. This a major problem, especially 
for individuals who are taking the same medications for multiple years, in some cases 
“over 10 years ago” (Pt. 11), and are not being reminded of the medication’s RFU, its 
benefits, and/or its potential conflicts with newer prescribed medications. 
 
Furthermore, the results from this study showed that RFU information is not 
consistently being provided to patients; the majority of the participants stated that 
they must ask the physician and/or pharmacist for the information, rather than it being 
provided openly. Some of the participants described this issue stating: 
 
“The doctors don’t tell you, they just prescribe it. They tell you to take it at such 
and such time, but they don’t tell you what they are for, unless you explicitly ask 
them. Even when you explicitly ask them some don’t tell you. So, you end up 
Googling it” (Pt. 3). 
 
“They usually give a very brief intro, ‘this is your problem and this is what can solve 
it’, but they don't go into detail unless I ask” (Pt. 5). 
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“I didn’t want to (ask) because she (physician) seemed very rushed. To her, my 
condition seemed very minor...she seemed almost dismissive and didn't want to 
help” (Pt. 6). 
 
Conversations with the patient are helpful because they can enhance patient 
understanding in a manner that contributes to better outcomes. Weston (2001) has 
argued that shared decision making is the crux of patient-centered care so when RFU 
information is provided to patients, it should be done in an appropriate manner. As 
professionals in the field, healthcare providers should check to make sure patients 
are understanding the drug regimen and RFU information adequately.  
 
  A previous study conducted at the University of Waterloo identified patients as 
the key point for transferring information on medications from the physician to the 
pharmacist (Grindrod, Tran, & Burns, 2015); this is especially difficult when patients do 
not adequately understand RFU and increasingly difficult for patients, particularly 
those with complex polypharmacy, who must coordinate medications over multiple 
specialists and settings. This is an exceptionally cumbersome task for these 
individuals, with substantial leeway for errors. One stakeholder described the 
situation as: 
 
“I switched pharmacies for that very reason. I was connected with a large 
multinational chain and I was just a number to them. Every time I went in, I 
had to retell my story, re-ask my questions, so I switched to a much smaller 
tinier pharmacy” (Pt. 7). 
 
Several of the participants expressed that they would not take a medication 
without knowing the reasoning behind it; if for some instance the participant was not 
counseled properly on RFU, it could potentially affect their adherence to the drug 
regimen. Patients provided with RFU information has been shown to help facilitate 
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patient adherence and fewer errors (Kuntz et al., 2014; Schiff et al., 2016).  Some of the 
participants described this issue stating: 
 
“I think it would mostly just reemphasize the importance of me taking the 
medication because it would be a good way to remind myself of why I'm taking 
it if for some reason I've been on it a very long time” (Pt. 2). 
 
“It will help me prioritize medications. Like if it’s an antibiotic, I can’t miss it, skip 
that, or break the course, I have to take it through the entire thing, otherwise, it 
would make the antibiotic ineffective and create more problems. So, it’s 
absolutely important to know what I can’t skip. It’s worth knowing the 
information of what it’s for” (Pt. 3). 
 
While providing RFU information is undoubtedly an important factor in 
increasing patients’ understanding of their medications, professionals (healthcare 
providers and government agencies) should take in account that only providing this 
information only verbally may not be sufficient. Results from this showed that many 
of the participants rely on their memory for storage and retrieval of RFU information. 
Given that memory and information retrieval decrease with age and the likelihoods of 
polypharmacy increasing with age, it is important to consider other channels of 
sharing RFU, such as pharmacist printing out a medication list with RFU included, 
providing patients with an online portal to access their medication history, or printing 
RFU on the patient’s prescription label (Chapter 5). 
 
Overall, results from this study showed that patients are very positive about including 
RFU into the current Ontario health care system. There are several reasons why 
knowledge of a medication’s reason for use would be beneficial for all stakeholders 
(patients, physicians, and pharmacists); reasons confirmed from this study include: 
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A. Off-label use – Off-label use is the use of pharmaceutical drugs for an unofficial 
indication and/or in an unapproved age bracket, dosage, or method of 
administration (Stafford, 2008). Prescription drugs can be used in off-label 
manners. In a Quebec electronic health record, it was found that 1 in 10 
prescriptions were written for off-label use and a large majority of these 
prescriptions (79%) lacked strong evidence for use (Eguale et al., 2012).  
 
B. Identification – Knowing a medication’s purpose reduces errors due to look-
alike/sound-alike medications (e.g., hydrochlorothiazide for hypertension vs. 
hydroxychloroquine for rheumatoid arthritis). When RFU information is added 
to a prescription, pharmacists are able to identify twice as many discrete 
medications with look-alike names (Kennedy, Littenberg, Callas, & Carney, 
2011). This same notion can assist patients in discerning between their 
prescribed medication that look-alike/sound-alike. 
 
C. Patient Knowledge - Almost 1 in 8 patients cannot accurately communicate 
what a medication has been prescribed for (Persell et al., 2004). Patients are 
able to remain safer in terms of their prescription use and adherence when they 
have been provided with RFU information  (Kuntz et al., 2014; Schiff et al., 2016). 
 
Schiff and colleagues are presently working to design a particular type of RFU 
field known as “indication-based prescribing.” It is assumed that the RFU information 
is the “link connecting a patient with a given drug,” and that health systems need to 
incorporate this missing link (Schiff et al., 2016). Thus, incorporating RFU into the 
Ontario health system is an undeniably virtuous opportunity for improving the safety 
and quality of patient care. Accordingly, this research study serves as an important 








 This study had some limitations.  First, there was a small sample size for 
the patient interviews. We used a convenience sampling, as an unintended 
result, generalizability and representativeness may be limited (not all the 
participants are considered polypharmacy patients), Thus, the views expressed 
in interviews do not necessarily represent those of the broader community. 
Also, our study did not include significant numbers of low English proficient 
individuals or patients with low educational and/or health literacy skills; 
therefore, the study needs to be extended to these populations. Although 
pharmacist and physicians were not included in this research study, their views 
on the inclusion of RFU are needed; they are key members of the shared 
decision-making process, therefore future studies should include their 
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Chapter 5 Prototyping Findings from Design 
Workshop 
 
In the following chapter, an analysis of this exploratory research study is presented 
which sets out to answer the primary research question by understanding the design 
and preferences of RFU onto prescription labels through involving the key 
stakeholders: patients. Similar to the previous chapter, the purpose of this study is to 
understand how the RFU information can be included onto prescription labels to 
enhance patient understandings of their medication and to improve shared decision 





5.1.1 Description of the patient stakeholder sample 
 
15 participants took part in the design workshop portion of the study. 9 
(40%) participants were female and 6 (40%) were male; the mean age of the 
participants was 68.7 years. As seen in Table 5, Five (33.3%) individuals were 
currently taking three or four prescribed medications; six (40%) were currently 
taking five or six prescribed medications; five (26.7%) were currently taking 
seven or more prescribed medications. Participants were currently taking an 
average of 5.6 prescription medications. Twelve (80%) participants keep a list 
of their prescribed medications. Patients were further tested on their 
understanding of their own medications by going through each one 
independently and stating the RFU. Thirteen (86.7%) assuredly stated the RFU 
for their medications.  
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Table 5 Stakeholder demographics (n=15) from the design workshop 
 
 
 Frequency (%) 
Age (in years)  
21-40 1 (6.7%) 
41-60 2 (13.3%) 
61-80 7 (46.7%) 
81+ 5 (33.3%) 
Mean 68.7 
Gender  
Male 6 (40%) 
Female 9 (60%) 
Number of prescribed medications  
3 3 (20%) 
4 2 (13.3%) 
5 3 (20%) 
6 3 (20%) 
7+ 4 (26.7%) 
Mean 5.6 
Keeps list of medications  
No 3 (20%) 
Yes 12 (80%) 
Assuredly states RFU of their 
medications 
 
No 2 (13.3) 
Yes 13 (86.7) 
 
 
5.1.2 Adding RFU onto prescription labels 
 
  Results from the design workshop revealed that stakeholders preferred 
adding RFU onto prescription labels in the following locations: the top of the 
label (6.7%0, above the dosage instructions (13.3%), next to the dosage 
instructions (13.3%), underneath the dosage instructions (33.3%), and next the 
drug name (46.7%). As seen in Table 6, the majority (73.3%) of stakeholders felt 
that these locations were the most logical. Twelve (80%) of the participants 
would like the RFU detail to be written in short-hand (one to three words). As 
for rearranging the prescription label layout, the results were split with eight 
(53.3%) feeling that no changes were necessary and seven (46.7%) feeling like 
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the addition, removal, or rearrangement of information was necessary. The 
majority (86.7%) of the stakeholders had no concerns with adding RFU onto 
their prescription labels. Stakeholders would appreciate having RFU on their 
labels ‘always’ (53.3%), the first time a medication is filled (13.3%). Eight (53.3%) 
of the stakeholders expressed that other individuals may feel having such 
information on their prescription labels would invade their privacy. 
Stakeholders felt that the following individuals would benefit from having the 
RFU on prescription labels: family and/or partner (20%), older 
adults/cognitively impaired (33.3%), health providers (13.3%), and caregivers 
(13.3%). All but one stakeholder preferred the phrase ‘reason for use’ over 




Table 6 Stakeholder prescription label design preferences and insights 
 
 
Question FREQUENCY (%) 
Responses to interview questions  
RFU location preference  
Top of label 1 (6.7) 
Above dosage 2 (13.3) 
Next to dosage 2 (13.3) 
Underneath dosage  5 (33.3) 
Next to drug name 7 (46.7) 
Location reasoning  
Logical 11 (73.3) 
Visible 2 (13.3) 
Grabs attention 2 (13.3) 
More space 3 (20) 
RFU detail  
Short 12 (80) 
Long 2 (13.3) 
Depends 1 (6.7) 
Label rearrangement  
No 8 (53.3) 
Yes 7 (46.7) 
Concerns  
None 13 (86.7) 
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Privacy 1 (6.7) 
Abuse 1 (6.7) 
When RFU is wanted on the label  
Always 8 (53.3) 
First fill (new medication) 2 (13.3) 
Unsure 4 (26.7) 
Not wanted 1 (6.7) 
When RFU is not wanted on the label  
Privacy (for self) 1 (6.7) 
Privacy (for others) 8 (53.3) 
Unsure 6 (40) 
Who would benefit  
Family/partner 3 (20) 
Older adults/cognitively impaired 5 (33.3) 
Health providers 2 (13.3) 
Caregivers 2 (13.3) 
Everyone 5 (33.3) 
‘Reason for use’ vs. ‘Reason to use’ 
(RTU) 
 
RFU 14 (93.3 





To the best of the researcher’s knowledge, this is the first study that has 
examined the preference of the patient stakeholders for a newly designed label that 
includes RFU. The design requirements for adding RFU information onto prescription 
labels were explored, following the guidance obtained from the design workshop. 
The design workshop aimed to explore the language, amount of detail, location, the 
presentation of the reason to use information, and the overall layout preference of 
prescription labels. The results from this study showed that patients prefer RFU 
underneath the dosage instructions or next to the drug name, as shown in Figure 2. 
The stakeholders felt these locations were “almost logical” (Pt. 6). One participant who 
preferred RFU next to the dosage instructions supported their design choice by 
stating: 
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“I think that's where I would go because that really tells you-I mean this is the 
important stuff. You need to know how many times and for how long and then 




Figure 2 Participants preferred RFU Location 
 
 
Findings from the discovery phase (Chapter 4) and literature (Chapter 2) 
suggest avoiding medical jargon on prescription labels and that same principle 
should be applied to implementing RFU on prescription labels. Results from this study 
showed that the RFU language should be concise (one to three words) to serve as a 
“memory trigger” (Pt. 6). If the RFU information is too long, there’s a risk that patients 
will not read it or understand it completely. One stakeholder described this situation 
as: 
 
“If it gets too long or complicated, there would be some people that do not grasp 
it all” (Pt. 17). 
 
Aside from implementing RFU onto prescription labels, results from this study 
showed that some stakeholders preferred the content on the label to be removed, 
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information as shown in Figure 3. The majority of the participants found nothing that 
was ‘not useful’ with the prescription label. One study found that the average patient 
found their own prescription labels generally easy to read, understand and useful 
(Law & Zargarzadeh, 2010). Similarly, older patients have a schema that they use to 
understand drug information, and they prefer information to follow in that order (D G 
Morrow, Leirer, Andrassy, Hier, & Menard, 1998; William J. Vigilante & Michael S. 
Wogalter, 1997). It is posited that the findings from this study were partially due to 
familiarity with existing label formats. However, the results from this study also 
suggest that improvements could be made that may help all patients. These changes 





Figure 3 Participants preferred prescription label changes 
 
 
Although the benefits of having RFU have been detailed throughout this thesis, 
there are some concerns about the inclusion of such information on prescription 
labels. The most prominent concern amongst the participants pertains to privacy. 
Privacy concerns were more evident amongst the younger participants (age 40 and 
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the use of medications that may have a stigma associated with them. One participant 
stated that,  
 
“If somebody sees this in my medicine cabinet, they don’t necessarily know what 
it’s for but, with RFU it’s more obvious to others. So, if I am carrying something that 
says ‘for depression,’ I am not comfortable sharing that I suffer from depression or 
battle depression. It takes that freedom to share or not away” (Pt. 6). 
  
The implications of RFU associated with the treatment of depression, HIV/Aids, 
STDs, and condition alike should be assessed more carefully (Law & Zargarzadeh, 
2010; Sakharkar et al., 2014). One way to afford these privacy concerns is giving the 
patient the option to not disclose this information on their prescription label. 
 
Ultimately, the benefits associated with adding RFU to the label allows patients 
to gain a better understanding of why they are being given a medication by their 
doctors, and this enables them to answer questions or deny the medication if they 
feel that it is unsafe (McNaughton, Huet & Shakir, 2014). The design of RFU should use 
lay language, be simple (containing one to three words, e.g. ‘for strep throat’), and 
should be placed in a sensible location either underneath to the dosage instructions 
or next to the drug name. 
 
5.2.1  Limitations 
 
This study had some limitations.  First, there was a small sample size for 
the patient interviews. We used a convenience sampling, as a result, 
generalizability and representativeness may be limited (not all the participants 
are considered polypharmacy patients), Thus, the views expressed in 
interviews do not necessarily represent those of the broader community. Also, 
our study did not include significant numbers of low English proficient 
individuals or patients with low educational and/or health literacy skills; 
therefore, the study needs to be extended to these populations. We cannot 
   
46 
assume that patients fully understand the RFU information on prescription 
medication containers, because their appearance suggests that they are 
simple and clear., therefore, further research needs to be done to clarify the 
real value and comprehensibility of RFU on the label for patients and their 
impact on final health outcomes. Lastly, although pharmacist and physicians 
were not included in this research study, their views on the inclusion of RFU 
onto prescription labels are needed; they are key members of the shared 
decision-making process, therefore future studies should include their 
opinions on the augmentation of RFU onto prescription labels.   
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Chapter 6 Conclusion and Future Work 
 
This research was an initial attempt to understand the need for adding RFU 
onto prescription labels and the design of such. This exploratory study employed co-
design strategies through semi-structured interviews and a design workshop with 
patient stakeholders was conducted to investigate design requirements for this 
patient-centered label. When patients are not clear about what their prescriptions do, 
it is possible that they are being treated for symptoms that deviate from their main 
complaints, and this limits their ability to discuss the matter further with their 
prescribers (Hassell, Noyce, Rogers, Harris & Wilkinson, 1998).  
 
The data gathered through the semi-structured interviews and design 
workshop indicated that RFU may have an important role in increasing patient 
understanding of their medication and ultimately, increase patient-safety. Results 
from the first part of the study showed that patients are currently receiving RFU 
information verbally from their physician and/or pharmacist when it a newly 
prescribed medication and/or upon asking. Currently, participants rely on their 
memory for the storage and retrieval of RFU information, but would like to have this 
information provided to them in a written manner (i.e. a printed medication list, an 
online health portal, or on their prescription labels). Participants were generally 
receptive of including RFU into the health care system, concluding that access to 
such information would increase their understandings of their medications. 
Requirements for adding RFU to prescription labels should meet the following 
criteria: be placed underneath the dosage instruction or next to the drug name; be 
written in one to three words; and written in lay language as shown in Figure 4. 




Figure 4 Examples of prescription labels with RFU design requirements 
 
 
Picking up a pill bottle and following the instructions for use is a patient-
centered activity. It is important to note, however, that the inclusion of RFU on 
prescription labels may not meet the wants and needs of every patient or may not be 
appropriate in all patient care situations (American Pharmacists Association, 2017; 
Shiyanbola et al., 2016). Designers focused on implementing RFU on prescription 
labels should prioritize designs that provide the best features in terms of efficiency 
and safety, rather than only focusing on the design that is most preferred by users as 
it has been noted in human factors and systems design that there may be 
dissociations between performance and user preferences (Andre & Wickens, 1995). 
 
Previous research has also shown that the other stakeholders may benefit from 
the inclusion of RFU in the Ontario health care system. Including RFU as a part of 
medication ordering practices ensures that the RFU will be accurately transcribed by 
the pharmacists or members of the pharmacy staff who are tasked with printing labels 
(Schiff et al., 2016). As the current Ontario health system stand, patients are the 
fundamental source for the accurate transfer of information between different 
physicians, pharmacist, and other healthcare providers they are working with. By 
providing patients RFU on their prescription labels, the exactitude of transfer such 
information may be enhanced, which ultimately benefits the healthcare providers in 
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The American Pharmacist Association (APhA) encourages pharmacists to 
include RFU on prescription labels, stating that “when such information is included by 
the prescriber on the prescription order or can be otherwise clearly and accurately 
discerned per the professional knowledge and judgment of the pharmacist” 
(American Pharmacists Association, 2017). Future studies should include the opinions 
of pharmacist because are they are the health providers who would ultimately 
dispense and elucidate the revised labels during medication counseling and they 
may be the first health provider to notice a patient’s misunderstanding on how to 
safely use their prescription medications (American Pharmacists Association, 2017). 
 
 It has been found that pharmacists view this change favorably to improve 
patient understanding and medication adherence, but have some hesitations due to 
implementation costs (Institute of Medicine, 2006; Mohan et al., 2013; Sakharkar et al., 
2014). Considering the practice and policy implications of this research, the cost 
attached to adding RFU into the health care system, changing the prescription label, 
and how these changes may impact policy implications in terms of state-board-
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Appendix A Semi-Structured Interview 
Recruitment Poster 
 
Department of Systems Design Engineering University of Waterloo 
 
 
PARTICIPANTS NEEDED FOR 
RESEARCH ON PHARMACY MEDICATION LABELS 
 
We are looking for volunteers to take part in a study, “exploring reason to use.” As a participant of this 
study, you would be asked questions regarding how medication labels can include the reason a drug 
is being used. 
 
Your participation would involve a 45-minute interview. 
In appreciation for your time, you will receive $25 cash! 
 
Participants must meet the following criteria: 
be 18 years and older, be able to speak English fluently, 
are currently taking 3 or more medications. 
 
For more information about this study, or to volunteer for this study,  
please contact: 
 
Reicelis Casares Li 
PhD, Systems Design Engineering 
Email: rcasares@uwaterloo.ca 
Or 
Catherine Burns, Professor 
Executive Director, Centre for Bioengineering and Biotechnology 
at 519-888-4567 Ext. 33903 or  
Email: catherine.burns@uwaterloo.ca  
 
This study has been reviewed by, and received ethics clearance  
through the University of Waterloo Research Ethics Committee. 
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Appendix B Design Workshop Recruitment 
Email 
 
Hello (insert name), 
 
My name is Thana and I am a graduate researcher at the University of Waterloo with 
the Systems Design Engineering Department. We are conducting a study regarding 
adding indication, what we refer to as “reason for use” onto prescriptions that are sent 
from physicians to pharmacist and furthermore, adding “reason for use” information 
onto prescription labels. We are looking for individuals who take 3 or more prescribed 
medications.  
 
Your participation would involve an interview and a design session, which in total will 
take 45 minutes. In appreciation of your time, you will be given $25 cash. 
  
Would you be interested in participating in this study? Feel free to reply to this email 
with your answer If you have any further questions please do not hesitate to contact 
me. 
 




Thana G. Hussein 
MASc Candidate Systems Design Engineering 
Advanced Interface Design Lab 
University of Waterloo 
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Appendix D Project Summary 
 
Dear Potential Participant, 
 
This letter is an invitation to consider participating in a research study we are 
conducting in the Department of Systems Design Engineering and the School of 
Pharmacy at the University of Waterloo under the supervision of Dr. Catherine Burns 
and Dr. Kelly Grindrod 
 
The purpose of this study is to understand how “reason to use” information can be 
shared amongst pharmacist, physician, and patients to improve decision making. The 
term reason for use it is used to convey why the medication it is prescribed. The 
rationale is that 7% of the population takes at least one medication, and almost a third 
of seniors take 5 or more medications. Nearly half of the population do not or cannot 
take their medications as prescribed, causing many preventable medication-related 
hospitalizations. Adverse drug events are the cause of one in every nine emergency 
room visits, costing the Canadian health care system over $2 billion each year. With 
an aging population, medication risks will only escalate. Poor knowledge-sharing 
within health care teams is a vital factor of medication mismanagement. One potential 
solution for these mishaps is to include the “reason for use” information with the 
prescriptions given to pharmacists and patients. 
 
Participation in this study is voluntary. Participation requires an interview and a design 
workshop of approximately 45 minutes at a mutually agreed upon location. You may 
decline to answer any of the interview questions if you wish. Furthermore, you may 
decide to withdraw from this study without any negative consequences by advising 
the researcher; you will have up to two months after the interview has been 
conducted to do so. With your permission, the interview will be audio recorded to 
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facilitate collection of information, and later transcribed for analysis. The dataset 
without identifiers may be shared publicly. Your identity will be confidential, it will not 
appear in any thesis or report resulting from this study, however, with your permission 
anonymous quotations may be used. Please be advised, however, that confidentiality 
will be in accordance to Article 5.1 of the of the Tri-Council Policy Statement. 
Confidentiality will be balanced against competing ethical considerations or legal or 
professional requirements that call for disclosure of information obtained or created 
in this research context. Data collected during this study will be retained for a 
minimum of 7 years in a locked office. Only researchers associated with this project 
will have access. Your name and any identifying data will not be shared with the study 
sponsors.  
 
There are no known or anticipated risks to you as a participant in this study. There are 
unlikely to be any direct benefits to the participants of this study. The intention of this 
project is to use the information gathered to help Electronic Health Record (EHR) 
vendors redesign their electronic medical and pharmacy records. The ultimate 
beneficiaries will be patients and clinicians who will use the new systems that are 
designed for medication management. 
 
Once all the data collected from this project has been analyzed thoroughly, I plan on 
sharing the results with the research community through seminars, conferences, 
presentations, and journal articles. 
 
Each participant will receive an honorarium of $25.  
 
This study has been reviewed and received ethics clearance through a University of 
Waterloo Research Ethics Committee (ORE# 22713). If you have questions for the 
Committee, contact the Office of Research Ethics by phone at 1-519-888-4567 ext. 
36005 or by email at ore-ceo@uwaterloo.ca.   
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For all other questions, or, if you would like additional information to assist you in 
reaching a decision about participation, please contact me, Reicelis Casares Li, by 
email at rcasares@uwaterloo.ca. You can also contact my supervisor, Dr. Catherine 
Burns by phone at 519-888-4567 ext. 33903 or by email at 
catherine.burns@uwaterloo.ca.  
 
I hope that the results of my study will be of benefit to those organizations directly 
involved in the study, as well as to the broader research community. 
 





Reicelis Casares Li, PhD 
Postdoctoral Fellow 
Advanced Interface Design Lab 
Department of Systems Design 
Engineering  




Advanced Interface Design Lab 
Department of Systems Design 
Engineering 
University of Waterloo 
tghussei@uwaterloo.ca 
 
Catherine Burns, PhD, Professor, Systems Design Engineering, University of 
Waterloo. Tel: (519) 888-4567 ext. 33903. Email: catherine.burns@uwaterloo.ca  
 
Kelly Grindrod, BScPharm, MSc, PharmD, Assistant Professor, University of Waterloo 
School of Pharmacy, 200 University Avenue West, Waterloo, ON N2L 3G1. Phone: 
519.888.4567 ext. 21358. Email: kgrindrod@uwaterloo.ca 
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Appendix E Participant Consent Form 
 
By signing this consent form, you are not waiving your legal rights or releasing the 




I have read the information presented in the information letter about a study being 
conducted by Catherine Burns, Kelly Grindrod, of the Department of System Design 
engineering and the School of Pharmacy at the University of Waterloo. I have had the 
opportunity to ask any questions related to this study, to receive satisfactory answers 
to my questions, and any additional details I wanted. 
 
I am aware that I have the option of allowing my interview to be audio recorded to 
ensure an accurate recording of my responses. 
 
I am also aware that excerpts from the interview may be included in the thesis and/or 
publications to come from this research, with the understanding that the quotations 
will be anonymous. 
 
I was informed that I may withdraw my consent without penalty by advising the 
researcher, it was communicated to me that I have 2-months after my interview was 
conducted for it. 
 
This study has been reviewed and received ethics clearance through a University of 
Waterloo Research Ethics Committee (ORE# 22713). If you have questions for the 
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Committee contact the Chief Ethics Officer, Office of Research Ethics, at 1-519-888-
4567 ext. 36005 or ore-ceo@uwaterloo.ca.  
 
For all other questions contact Catherine Burns by phone at 519-888-4567 ext. 33903 
or by email at catherine.burns@uwaterloo.ca. 
 
With full knowledge of all foregoing, I agree, of my own free will, to participate in this 
study. 
☐YES   ☐NO   
I agree to have my interview audio recorded. 
☐YES   ☐NO   
I agree to the use of anonymous quotations in any thesis or publication that comes of 
this research. 
☐YES   ☐NO 
 
Participant Name: ____________________________ (Please print)   
Participant Signature: ____________________________  
Witness Name: ________________________________ (Please print) 
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Appendix F Semi-Structured Interview 
Questions 
 




1. What is your age? 
 





Questions related to your medication history: 
 
1. How many medications do you take regularly?  
 
2. In the last month, can you tell me what medications you took and why you 
took each of your medications? 
3. Do you keep any lists of these medications (in a file, on a computer, etc.)? 
 
4. Would you be comfortable with us taking a picture of these records? We 
will ensure that all identifying information is kept confidential and protected. 
 
   
74 
We are going to talk about how you interact with the current system. In particular we are 
interested in something called “reason for use”. This is the reason a medication was 
prescribed to you. For example, the reason for use with Tylenol may be “a headache” our 
“arthritis pain”. 
 
Questions related to how you function in the current system: 
 
1. How do you currently find out what your medications are for? 
 
2. Where do you place this information? (Potential probes: Do you write it 
down? Do you keep it put in your phone? Do you make medication lists?) 
 
3.  In the past, has the reason for use information been shared with you? 
a. Who shared this type of info with you? Pharmacist? Physician? 
b. When did they share it?  Did you have to ask to find out or was this 
info provided? 
c. Please provide an example of what type of language was used to 
explain a medication. How useful was this? 
d. Was there a time that the reason for using a medication a 
professional provided was not clear or useful?  Please explain.  
e. Can you recall a time that learning the reason for using a medication 
was particularly helpful for you?  Please tell me more.  
 
4. Who else is aware of the reasons you are taking your medications? 
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5. Can you recall a time when you did not know the reason for a medication? 
What implications did this have?  
a. What did you do to find out (if appropriate to ask)? (ask user to draw 
out the steps they took to find out the reason for use information) 
 
6. On a scale of 1 to 5, with 5 being “very important,” how important is it for you 
to know what your medication are for? Please tell us more. 
 
We are going to talk about what would happen if the "reason to use" was added to the 
computer systems that doctors, pharmacists, and nurses use to help you manage your 
medications. 
 
Questions related to being provided with “reason to use” information: 
 
1. How would you feel if the reason for use was shared with your pharmacist 
on every prescription, including refills? 
 
2. How should the reason for use information be presented to you? (Probing 
questions: Would you like it to be on your prescriptions? Receipts? 
Medication lists? In an app or website that you use to view or access your 
prescriptions?) 
 
3. How would the reason for use information affect your ability to make 
decisions about your medications? 
 
   
76 
4. Who else should have access to your reason for use information? This can 
be anyone in your life such as healthcare professionals, care providers, or 
family members. Why? 
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Appendix H Design Workshop Prescription 
Label Cut-Out Information 
 
Pharmacy Name LOCAL PHARMACY 
Pharmacy Address 




Prescription Fill Date 15-MAY-2018 
Name of Prescriber DR. T MEDICINE 
Prescription Number RX: 123456789 
Your name (patient’s 
name) PATIENT, NAME 
Number of refills 
remaining REF: 0 
Directions on how to 
take the medication 
TAKE 1 CAPSULE THREE TIMES 
DAILY FOR TEN DAYS 
Brand name of 
medication ABC-AMOXICILLIN 500 MG 
Generic name of 
medication AMOXICILLIN 500 MG 
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Quantity and form of 
medication dispensed 30 CAPSULES 






Number (DIN) 0123456 
Reason the drug is 
prescribed REASON TO USE 
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Appendix I Design Workshop Questions 
 
Thank you all for joining us today in this co-design workshop. As a reminder, 
today we will be designing prescription labels with the addition on reason for use 
information. The term reason for use it is used to convey why, specifically, the 
medication it is prescribed. This information is important to have as many medications 
have multiple reasons for use which affect the dose, route, duration, frequency of use, 
or monitoring needs. Without an understanding of the reason a medication is 
prescribed, individuals are not able to assess if a prescription is appropriate or safe. 
Today we will be focusing on how that information should look and where that 
information should be placed on the label. 
 




1. What is your age? 
 





Questions related to your medication history: 
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1. How many medications do you take regularly?  
 
2. In the last month, can you tell me what medications you took and why you 
took each of your medications? 
3. Do you keep any lists of these medications (in a file, on a computer, etc.)? 
 
4. Would you be comfortable with us taking a picture of these records? We 
will ensure that all identifying information is kept confidential and protected. 
 
(Hand participant example prescription label template and example prescription 
label template) 
 
Please place an ‘X’ where you would want to see “reason to use” information. 
 
1. Why did you choose this location? 
 
2. How much detail would you expect the RFU information to be? (Potential 
probes: Short-hand? Long-hand?) 
 
If you could add, remove, or rearrange the information on this prescription label, would 
you? 
 
If yes:  please show us what you’d like to see differently. 
 
(Hand participant blank prescription label template, corresponding prescription label 
information, scissors, and tape) 
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1. Why did you choose the layout you did?    
 
(Walk through patient’s design choices and probe to understand their design-
decision making process) 
 




1. Do you have any concerns regarding the sharing of reason for use information 
with the pharmacist or on your prescription labels? If so, what? 
 
2. On what occasion(s) would you like this information on your prescription label? 
 
3. On what occasion(s) would you not like this information on your prescription 
label?  
a. (if they acknowledge privacy concern) How you suggest affording 
privacy concerns? 
 
4. Do you prefer the phrase ‘reason to use’ or ‘reason for use’? 
 
5. Who do you think would benefit from this new design? 
 
6. Do you have any final thoughts, comments, or concerns? 
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Thank you for your participation in our research study entitled, “Exploring how ‘reason 
to use’ information can be shared between pharmacists, physicians, and patients.” As 
a reminder, the purpose of this study is to understand how “reason to use” information 
can be shared to improve decision making among pharmacist, physician, and 
patients. 
 
The information collected during interviews will lead us to a better understanding of 
how the "reason to use" information can improve shared decision-making process 
between physicians and pharmacist. This information will be especially useful in 
situations where physician and pharmacist are working with patients who are taking 
multiple medications.   
 
This study has been reviewed and received ethics clearance through a University of 
Waterloo Research Ethics Committee (ORE# 22713). If you have questions for the 
Committee, contact the Office of Research Ethics by phone at 1-519-888-4567 ext. 
36005 or by email at ore-ceo@uwaterloo.ca.  
For all other questions contact Catherine Burns, Executive Director, Centre for 
Bioengineering and Biotechnology, by phone at 519-888-4567 Ext. 33903 or email at 
catherine.burns@uwaterloo.ca. 
 
As a reminder, any data pertaining to you as an individual participant will be kept 
confidential. Please be advised, however, that confidentiality will be in accordance to 
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Article 5.1 of the of the Tri-Council Policy Statement. Confidentiality will be balanced 
against competing ethical considerations or legal or professional requirements that 
call for disclosure of information obtained or created in this research context. Once 
all the data collected from this project has been analyzed thoroughly, I plan on 
sharing the results with the research community through seminars, conferences, 
presentations, and journal articles.  
 
If you are interested in receiving more information regarding the results of this study, 
or would like a summary of the results, please provide your email address for us to 
forward the results to. In the meantime, if you have any questions about the study, 
please do not hesitate to contact me at the email provided below. 
Yours sincerely,  
 
Reicelis Casares Li, PhD 
Postdoctoral Fellow 
Advanced Interface Design Lab 
Department of Systems Design 
Engineering  




Advanced Interface Design Lab 
Department of Systems Design 
Engineering 
University of Waterloo 
tghussei@uwaterloo.ca 
 
 
 
